Chris Bayly
Papers
1
Total Citations
39
H-Index
1
About
Chris Bayly is a distinguished researcher in the fields of drug discovery, high-throughput screening, and neuropharmacology, with a particular focus on metabotropic glutamate receptors (mGluRs). His major contribution lies in pioneering automated screening methodologies to identify novel antagonists for these receptors, which are critical targets for treating neurological disorders such as anxiety, schizophrenia, and chronic pain. In his seminal 2003 paper, "Identification of metabotropic glutamate receptor antagonists using an automated high-throughput screening system," Bayly demonstrated how integrating robotics and assay miniaturization could accelerate the discovery of selective mGluR modulators—a breakthrough that has influenced subsequent drug development pipelines. This work, cited 39 times, underscores his role in bridging chemical biology and translational neuroscience. Beyond this, Bayly’s achievements include advancing assay design for G-protein-coupled receptors and contributing to the broader adoption of automation in pharmaceutical research. His efforts have not only deepened understanding of glutamatergic signaling but also provided practical tools for identifying therapeutic candidates, making his research a cornerstone for students and scientists interested in high-throughput screening and CNS drug discovery.
Research Focus
Key Achievements
Top Papers
- 1